Amarantus BioScience Content
1
Twitter $AMBS opened IND application to advance #eltoprazine into Ph 2b trial: [link] #levodopa-induces #dyskinesia Ph 2a study results published in @Brain1878 for the treatment of #Parkinson #levodopa-indices #dyskinesia [link] $AMBS $AMBS receives notice of allowance from U.S patent app for proprietary methods of admin of #eltoprazine: [link] Corp & clinical devl achiev for the Therapeutics division & subsidiary Amarantus Diagnostics Inc. in 1Q [link] $AMBS Click to learn about $AMBS Q1 financial results and business overview [link] #eltoprazine #dyskinesia $AMBS management to host conference call and webcast on Wednesday May 27 at 5pm EDT:[link] Facebook/Google+/Linkedin Amarantus expects eltoprazine phase 2b clinical program to commence in the second quarter of 2015.“One of our key priorities has been to prepare for the initiation of the Phase 2b clinical study of our lead therapeutic product candidate, eltoprazine, in Parkinson’s disease levodopa-induced dyskinesia,” said CEO Gerald Commissiong, “We have made tremendous progress moving this forwards and are on track to commence the study this quarter.” [link]
-
Upload
shannon-prenetta -
Category
Documents
-
view
18 -
download
0
description
Amarantus practice content
Transcript of Amarantus BioScience Content
Twitter$AMBS opened IND application to advance #eltoprazine into Ph 2b trial: [link] #levodopa-induces #dyskinesia
Ph 2a study results published in @Brain1878 for the treatment of #Parkinson #levodopa-indices #dyskinesia [link] $AMBS
$AMBS receives notice of allowance from U.S patent app for proprietary methods of admin of #eltoprazine: [link]
Corp & clinical devl achiev for the Therapeutics division & subsidiary Amarantus Diagnostics Inc. in 1Q [link] $AMBS
Click to learn about $AMBS Q1 financial results and business overview [link] #eltoprazine #dyskinesia
$AMBS management to host conference call and webcast on Wednesday May 27 at 5pm EDT:[link]
Facebook/Google+/LinkedinAmarantus expects eltoprazine phase 2b clinical program to commence in the second quarter of 2015.“One of our key priorities has been to prepare for the initiation of the Phase 2b clinical study of our lead therapeutic product candidate, eltoprazine, in Parkinson’s disease levodopa-induced dyskinesia,” said CEO Gerald Commissiong, “We have made tremendous progress moving this forwards and are on track to commence the study this quarter.” [link]
